Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Immunosuppressants and multiple sclerosis].

J L Ruiz-Peña1, G Izquierdo-Ayuso

  • 1Hospital Universitario Virgen Macarena, Sevilla, España. jlruizpe@hotmail.com

Revista De Neurologia
|September 18, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Attentional networks in neurodegenerative diseases: anatomical and functional evidence from the Attention Network Test.

Neurologia·2022
Same author

Effectiveness of monopolar dielectric transmission of pulsed electromagnetic fields for multiple sclerosis-related pain: a pilot study.

Neurologia·2021
Same author

Attentional networks in neurodegenerative diseases: anatomical and functional evidence from the Attention Network Test.

Neurologia·2020
Same author

Rebound after discontinuation of teriflunomide in patients with multiple sclerosis: 2 case reports.

Multiple sclerosis and related disorders·2020
Same author

[Vitiligo with Koebner phenomenon in a patient with multiple sclerosis treated with alemtuzumab].

Revista de neurologia·2018
Same author

[Thalamic ischaemic stroke: an uncommon aetiology of "startle syndrome"].

Neurologia (Barcelona, Spain)·2010
Same journal

The Correlation Between and Variability of Three Balance Scales in the Assessment of Balance Function in Patients With Ataxia.

Revista de neurologia·2026
Same journal

Surgical Treatment of an Aneurysm in the Subacute Stage of Hemorrhagic Moyamoya Disease: Aneurysm Resection Combined With STA-MCA Bypass: A Case Report.

Revista de neurologia·2026
Same journal

Mapping the Evidence: Central Sleep Apnea Syndromes During Sleep and Stroke-A Scoping Review.

Revista de neurologia·2026
Same journal

Developmental and Epileptic Encephalopathy Due to a Novel <i>ARHGEF9</i> Deletion Variant: Case Series of Two Siblings.

Revista de neurologia·2026
Same journal

P300 Event-Related Potentials as Cognitive Biomarkers in Neurological and Neuropsychiatric Disorders: A Systematic Review.

Revista de neurologia·2026
Same journal

[Effectiveness and Risk of Recurrence of Pulsed Radiofrequency in Trigeminal Neuralgia and Chronic Cluster Headache].

Revista de neurologia·2026
See all related articles

Severe immunosuppression in multiple sclerosis (MS) reduces disease activity but causes significant side effects and does not halt progression. Further research is needed to optimize its use.

Area of Science:

  • Neuroimmunology
  • Clinical Neurology

Context:

  • Multiple Sclerosis (MS) presents diverse therapeutic challenges.
  • Advances in MRI and clinical trial design inform treatment strategies.
  • Animal models show promise but clinical translation varies.

Purpose:

  • To review the current status of immunosuppressant therapies for MS.
  • To analyze clinical trial data for specific immunosuppressants including cladribine, linomide, sulfasalazine, cyclophosphamide, mitoxantrone, cyclosporine A, and azathioprine.

Summary:

  • Severe, non-specific immunosuppression can decrease MS disease activity (lesions, clinical relapses).
  • Observed benefits include slight improvements in seizure rates and MRI findings.
  • However, this approach does not impact disease progression and carries substantial short- and long-term risks.

Related Experiment Videos

Impact:

  • Significant side effects can limit the administration of these immunosuppressants.
  • Methodological limitations may hinder definitive efficacy assessment.
  • Potential for improved outcomes exists with optimized dosing, combination therapies, or immunomodulators.